Pharmafile Logo

Medicine

- PMLiVE

Lundbeck completes patient randomisation for phase 3 trial for multiple system atrophy treatment

The rare neurodegenerative disorder has no cure and no approved treatments

- PMLiVE

Novo Nordisk elects employee representatives to Board of Directors

The elected employee representatives will join the Board of Directors after the annual general meeting on 26 March 2026

- PMLiVE

Johnson & Johnson’s multiple myeloma treatment approved by US FDA

The approval was based on phase 3 data showing survival rates of 83.3% after three years

- PMLiVE

Gilead Foundation announces $12m investment through HIV Prevention Initiative

The US state investment will go to 33 community-based organisations

- PMLiVE

Webinar: What do HCPs really want from pharma digital in 2026?

Our research shows that healthcare professionals are not disengaging from pharma digital. They are becoming more selective about the experiences that earn their attention. To explore what this means for...

Graphite Digital

Intelligent field team engagement: Turning shared knowledge into deeper insights and better decisions.

At Age of AI 2026, Inizio Medical’s Phil Wakefield and Inizio Ignite’s Tim Luxford will explore how cross-functional collaboration and AI can unlock faster, more actionable insights across medical and...

Inizio

- PMLiVE

GenAI: embracing the transformation – with caution

Despite the GenAI fervour, there is an acute need to prepare organisations to understand which specific tools they need and how to use them

- PMLiVE

AI in practice: 4 real-world use cases in health and life sciences

Artificial Intelligence (AI) is often discussed in broad terms, with promises of transformation at scale. In practice, however, its value is realized in far more specific ways – when it...

Inizio

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links